Ondine Biomedical Enrolls First Patient in US Phase 3 Trial

Ondine Biomedical Inc., a Canadian life sciences entity, has initiated its Phase 3 clinical trial by enrolling the first patient at Centennial Medical Center in Nashville, Tennessee. The trial, known as LANTERN, is set to involve around 5,000 participants across 14 hospitals. It aims to assess the efficacy of Ondine’s Steriwave®, a non-antibiotic nasal photodisinfection technology, in preventing surgical site infections.

Partnering with HCA Healthcare, this group-randomized crossover study will focus on patients undergoing various major surgical procedures. A comparison will be made between standard infection prevention practices and those incorporating the nasal photodisinfection technology. Preliminary results are anticipated by Autumn 2025.

Ondine’s CEO, Carolyn Cross, highlights the trial's significance in offering an innovative approach to pathogen elimination that circumvents issues of drug resistance.